PIK3CA and plasma cell myeloma: The importance of this agent was further revealed in a recent study that demonstrated that abrogation of PI3K using pan-PI3K inhibitor BKM120 decreased the survival of multiple myeloma cells via induction of caspase-3-dependent apoptosis, and it also produced a synergic anticancer effect when combined with carfilzomib [9].